Expert Opinion on Drug Safety

Toxicological and public good considerations for the regulation of nanomaterial-containing medical products
pp. 103-106(4)
Author: Faunce, Thomas A

The role of early in vivo toxicity testing in drug discovery toxicology
pp. 107-110(4)
Authors: Fielden, Mark R; Kolaja, Kyle L

The safety of dopamine agonists in the treatment of Parkinson's disease
pp. 111-127(17)
Authors: Bonuccelli, Ubaldo; Ceravolo, Roberto

Drug-induced mitochondrial dysfunction in cardiac and skeletal muscle injury
pp. 129-146(18)
Authors: Sardo, Vilma A; Pereira, Sandro L; Oliveira, Paulo J

Drug-induced crystal nephropathy: an update
pp. 147-158(12)
Authors: Yarlagadda, Sri G; Perazella, Mark A

Anticancer therapy in patients with porphyrias: evidence today
pp. 159-165(7)
Authors: Thiery-Vuillemin, Antoine; Chaigneau, Loic; Meaux-Ruault, Nadine; Villanueva, Cristian; N'guyen, Thierry; Maurina, Tristan; Stein, Ulrich; Lorgis, Vronique; Demarchi, Martin; Pivot, Xavier

The safety of diclofenac for the management and treatment of actinic keratoses
pp. 167-172(6)
Authors: Iraji, Fariba; Siadat, Amir Hossein; Asilian, Ali; Enshaieh, Shahla; Shahmoradi, Zabiholah

The effect of anticholinergic agents on gastro-oesophageal reflux and related disorders
pp. 173-180(8)
Authors: Soest, Eva M van; Dieleman, Jeanne P; Kuipers, Ernst J

Sudden cardiac death secondary to antidepressant and antipsychotic drugs
pp. 181-194(14)
Authors: Sicouri, Serge; Antzelevitch, Charles

Antiepileptic drugs as human teratogens
pp. 195-209(15)
Author: Eadie, Mervyn J

Corrigendum
pp. 211-211(1)